{1}

##LOC[OK]## ##LOC[Cancel]##

{1}

##LOC[OK]## ##LOC[Cancel]##

2nd Annual Mount Sinai MASLD/MASH Center of Excellence Symposium

Overview
Register
Faculty
Brochure

Add to Calendar 2nd Annual Mount Sinai MASLD/MASH Center of Excellence Symposium 10/11/2024 8:00:00 AM 10/11/2024 4:15:00 PM America/New_York For More Details: https://mssm.cloud-cme.com/MASH Description: Practitioners and researchers who are experts in the field of MASH will discuss current developments in the field. The intended audience includes primary care providers, endocrinologists, advanced practitioners, gastroenterologists, hepatologists, and others actively engaged in the diagnosis and management of MASH. Online false MM/DD/YYYY

Date & Location

Friday, October 11, 2024, 8:00 AM - 4:15 PM, Online

Target Audience

Specialties - Liver Diseases, Primary Care Physician

Course Overview

Practitioners and researchers who are experts in the field of MASH will discuss current developments in the field. The intended audience includes primary care providers, endocrinologists, advanced practitioners, gastroenterologists, hepatologists, and others actively engaged in the diagnosis and management of MASH.

Objectives

1) Demonstrate MASLD/MASH clinical course, risk stratification, outcomes, and disease management.
2) Interpret and appropriately apply results of non-invasive tests for MASLD/MASH to diverse patient populations

Accreditation

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credits

AMA PRA Category 1 Credits™ (7.00 hours), Non-Physician Attendance (7.00 hours)

It is the policy of the Icahn School of Medicine at Mount Sinai to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-provided educational activities. All faculty participating in the planning or implementation of a provided activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.

Mitigation of Relevant Financial Relationships

Icahn School of Medicine at Mount Sinai adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Anna Mageras, MPH
Mount Sinai
Sunnyside, NY

Course Director

Grant or research support-Gilead Sciences, Inc.|Grant or research support-Pfizer

Meena B. Bansal, MD

Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY

Course Director, Faculty

Advisor-Madrigal, NovoNordisk, Fibronostics, The Kinetix Group, Merck, Boeheringer-Inghelheim, Curve Bio|Consulting Fee-Madrigal, NovoNordisk, Fibronostics, Merck, Boeheringer-Ingelheim, CurveBio|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Intercept, Madrigal, NOVO Nordisk|Grant or research support-Histoindex, Pfizer

Scott L. Friedman, MD

Fishberg Professor of Medicine, Liver Diseases and Pharmacological Sciences
Icahn School of Medicine a Mount Sinai
New York, NY

Course Director, Faculty

Manal F Abdelmalek, MD, MPH, Professor of Medicine
Director, NAFLD Clinical Research
Mayo Clinic
Rochester, MN

Faculty

Naim Alkhouri, MD
Chief Medical Officer
Arizona Liver Health
PHOENIX, AZ

Faculty

Grant or research support-Madrigal|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Madrigal|Grant or research support-89 Bio|Grant or research support-Merck|Grant or research support-Gilead|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Pfizer|Speakers Bureau-Intercept Pharmaceuticals|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novo Nordisk|Grant or research support-Novo Nordisk

Andrea Branch, PhD
New York, NY

Faculty

Nothing to disclose

Fernando Carnavali, MD
MD
MSM-MSW
New York, NY

Faculty

Honoraria-Renalytix AI (KidneyIntelX) (Relationship has ended)

Jaime Chu, MD
Icahn School of Medicine at Mount Sinai
Manhasset, NY

Faculty

Consulting Fee-Albireo (Relationship has ended)

Tatyana Kushner, MD

Assistant Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, NY

Faculty

Advisor-Gilead|Consulting Fee-GlaxoSmithKline (GSK)|Grant or research support-Gilead|Advisor-Salix (Relationship has ended)

Anu Lala-Trinadade, MD

Assistant Professor of Cardiology, Population Health Science and Policy
The Mount Sinai Hospital
Edgewater, NJ

Faculty

Mazen Noureddin, MD
Houston Methodist Hospital
Houston, TX

Faculty

Advisor-Altimmune, BI, Cytodyn, 89BIO, GSK, (Relationship has ended)|Advisor-Lilly, Madrigal, Merck, Novo Nordisk, Terns and Takeda (Relationship has ended)|Grant or research support-Allergan, Akero, BMS, Gilead, Galectin, Genfit, GSK (Relationship has ended)|Grant or research support-GSK, Conatus, Corcept, Enanta, Madrigal, Novartis, Novo Nordisk, (Relationship has ended)|Grant or research support-Takeda, Terns, Viking and Zydus. (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Rivus Pharma, CIMA, Cytodyn, and ChronWell

Mary Rinella, MD
Professor of Medicine
University of Chicago Medicine
Chicago, IL

Faculty

Consulting Fee-Boehringer Ingelheim Boehringer Ingelheim|Consulting Fee-Intercept Pharmaceuticals|Consulting Fee-Madrigal|Consulting Fee-Novo-Nordisk

Jorn Schattenberg, MD
UKS
Homburg, Germany

Faculty

Consulting Fee-Akero, Alentis, Alexion, Altimmune, Astra Zeneca, 89Bio, Bionorica, Boehringer Ingelheim (Relationship has ended)|Consulting Fee-Gilead Sciences, GSK, HistoIndex, Ipsen, Inventiva Pharma, Madrigal Pharmaceuticals (Relationship has ended)|Consulting Fee-Lilly, MSD Sharp & Dohme GmbH, Nordic Bioscience, Northsea Therapeutics, Novartis, Novo Nordisk, (Relationship has ended)|Consulting Fee-Pfizer, Roche, Sanofi, Siemens Healthineers, Summit Clinical, and Vantage Biosciences Research (Relationship has ended)|Honoraria-AbbVie, Boehringer Ingelheim, Gilead Sciences, Ipsen Novo Nordisk, Madrigal Pharmaceuticals (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Hepta Bio.

Reshmi Srinath, MD
Assistant Professor of Medicine, Endocrinology
Icahn School of Medicine at Mount Sinai
New York, NY

Faculty

Bachir Taouli, MD

Professor, Department of Radiology, Translational and Molecular Imaging Institute (TMII)
Icahn School of Medicine at Mount Sinai
New York, NY

Faculty

Consulting Fee-Bayer|Consulting Fee-Guerbet|Grant or research support-Bayer Healthcare|Grant or research support-Takeda|Grant or research support-Guerbet

Augusto Villaneuva, MD
,

Faculty

Nothing to disclose

Friday, October 11, 2024

Introduction--the BIG Picture Metabolic Dysfunction Associated Steatohepatitis (MASH)
8:00AM - 8:15AM
Scott L. Friedman, MD

Hot Topics EASL Review of Emerging MASH Data
8:15AM - 8:35AM
Manal F Abdelmalek, MD, MPH, Professor of Medicine

Cracking the Code Making the Diagnosis, Risk Stratification, and Prognosis Prediction in MASLD/MASH
8:35AM - 8:55AM
Meena B. Bansal, MD

It’s Complicated Role of environmental and genomic factors on fibrosis progression in adults with MASH
8:55AM - 9:15AM
Andrea Branch, PhD

The Clues Within Overview of Serum Markers of Liver Fibrosis and Metabolic Health
9:15AM - 9:35AM
Mazen Noureddin, MD

Seeing is Believing Overview of Imaging Modalities for the Assessment of MASLD/MASH
9:35AM - 10:00AM
Bachir Taouli, MD

Break
10:00AM - 10:15AM

Powering the Future Leveraging New AI algorithms for Risk Stratification and Prediction of Outcomes
10:15AM - 10:35AM
Jorn Schattenberg, MD

Eye of the Storm Intersection of Genetics, Lifestyle, and Environment in Pediatric MASLD/MASH
10:35AM - 10:55AM
Jaime Chu, MD

Catch Me When You Can Maximizing Opportunities for Engagement by Screening for MASLD/MASH in OB/GYN
10:55AM - 11:10AM
Tatyana Kushner, MD

Screening for MASLD/MASH from PCP perspective
11:10AM - 11:30AM
Fernando Carnavali, MD

How to Talk to Patients Workshop Patient Panel/Real Time Needs Assessment
11:30AM - 12:15PM

Lunch
12:15PM - 1:00PM

Empowering Change Lifestyle, Medical, and Surgical Management of Obesity and Diabetes, and their Role in the Management of Patients with MASLD/MASH
1:00PM - 1:20PM
Reshmi Srinath, MD

Finding a Needle in a Haystack MASLD/MASH and HCC
1:20PM - 1:40PM
Augusto Villaneuva, MD

We have a drug for that Targeting Thyroid Hormone-b signaling and other emerging therapies in the treatment of MASH
1:40PM - 2:00PM
Meena B. Bansal, MD

Timing is Eveything GLP-1 (and combo drugs)-Mechanism of Action and their impact on MASH
2:00PM - 2:20PM
Mary Rinella, MD

The Crystal Ball Predicting and Managing Cardiovascular Risk in Patients with MASLD/MASH
2:20PM - 2:45PM
Anu Lala-Trinadade, MD

Break
2:45PM - 3:00PM

Ask the Experts Making Sense of It All (Case Based Discussion) and Open Q and A from attendees
3:00PM - 4:00PM
Meena B. Bansal, MD

Closing Remarks & Thanking Sponsors
4:00PM - 4:15PM